Results 331 to 340 of about 14,382,480 (395)
Some of the next articles are maybe not open access.
Haemophilia, 1995
The development of a Factor VIII inhibitor, an antibody that blocks its procoagulant function, is one of the most serious complications of hemophilia A treatment. Similar antibodies are also recognized as a rare cause of bleeding in previously healthy individuals who develop autoimmune anti-Factor VIII antibodies.
openaire +6 more sources
The development of a Factor VIII inhibitor, an antibody that blocks its procoagulant function, is one of the most serious complications of hemophilia A treatment. Similar antibodies are also recognized as a rare cause of bleeding in previously healthy individuals who develop autoimmune anti-Factor VIII antibodies.
openaire +6 more sources
Antihemophilic Factor (Factor VIII)
Annals of Internal Medicine, 1978Antihemophilic factor (Factor VIII) is an agent in normal plasma that corrects the coagulative defect of classic hemophillia. The plasma of hemophiliacs contains normal amounts of a variant of antihemophilic factor deficient in clot-promoting properties. In contrast, von Willebrand's disease is usually associated with a true deficiency of this protein.
openaire +3 more sources
FACTOR VIII AND GLOMERULONEPHRITIS
The Lancet, 1975To find out if determination of factor VIII,which most probably is synthetised in the intima of blood-vessesls, is of value for predicting the severity of vessel damge in glomerulonephritis, factor-VIII activity, factor-VIII-related antigen, and glomerular filtration-ratewere esto,ated om 85 patients with early glomerulonephritis on admission, and in ...
I. M. Nilsson, M. Ekberg
openaire +3 more sources
Activation, activity and inactivation of factor VIII in factor VIII products
Haemophilia, 2016IntroductionFactor VIII (FVIII) products used in haemophilia A treatment show inter‐and intra‐product and inter‐assay differences in specific activity. The mechanistic basis of these differences remains unclear.AimThe aim of this study was to mechanistically compare the functional properties of an in‐house excipient‐free full‐length FVIII standard and ...
R. Elsman +4 more
openaire +3 more sources
SUPPRESSION OF FACTOR VIII ANTIBODY BY COMBINED FACTOR VIII AND CYCLOPHOSPHAMIDE
Acta Medica Scandinavica, 1974Abstract. Four patients with severe haemophilia A complicated by inhibitors of factor VIII (corresponding to 0.5, 0.7, 1.0 and 2.5 U/ml plasma) and a non‐haemophilic woman with an acquired inhibitor of factor VIII (corresponding to 160 U/ml plasma) have been treated with a large single dose of factor VIII concentrate (4 000–8 000 U factor VIII) and ...
Inga Marie Nilsson +2 more
openaire +3 more sources
Scandinavian Journal of Haematology, 1980
Because of the need to relate haemophilic samples to the normal population, the unit of Factor VIII clotting activity (VIII:C) was first defined as the amount in 1 ml. of normal plasma. However, because of wide variation in the normal population, and poor stability of VIII:C in plasma, pooled normal plasma is unsuitable as a reference standard for ...
openaire +3 more sources
Because of the need to relate haemophilic samples to the normal population, the unit of Factor VIII clotting activity (VIII:C) was first defined as the amount in 1 ml. of normal plasma. However, because of wide variation in the normal population, and poor stability of VIII:C in plasma, pooled normal plasma is unsuitable as a reference standard for ...
openaire +3 more sources
In Vivo Interactions of Autoantibodies to Factor VIII with the Factor VIII Complex
Thrombosis and Haemostasis, 1982SummaryTwo non-haemophilic elderly patients who had developed autoantibodies to factor VIII were studied over a period of 9 months to 5 years. Sequential measurements of antibody to factor VIII (anti-VIII: C), factor VIII coagulant activity (VIII: C), factor VIII coagulant antigen (VIII: CAg), factor VIII-related antigen (VIIIR: Ag), and factor VIII ...
M P Croissant +5 more
openaire +3 more sources
Quantitative Evaluation of Factor VIII in Factor VIII Products.
Blood, 2004Abstract Several factor VIII products, recombinant and natural, have been used for hemophilia A treatment worldwide. Typically, two activity-based assays (factor Xase and aPTT) are used for the assessment of factor VIII concentration in these products.
Behnaz Parhami-Seren +4 more
openaire +2 more sources
JAMA: The Journal of the American Medical Association, 1986
To the Editor.— Rock et al 1 reported that in studies in 1982, the stated content of ampules of lyophilized antihemophilic factor (AHF, factor VIII) concentrates often exceeded the measured content, as assayed in the authors' laboratory. They stated that this discrepancy, with its implications of systematic undertreatment of classic hemophilia, has ...
openaire +3 more sources
To the Editor.— Rock et al 1 reported that in studies in 1982, the stated content of ampules of lyophilized antihemophilic factor (AHF, factor VIII) concentrates often exceeded the measured content, as assayed in the authors' laboratory. They stated that this discrepancy, with its implications of systematic undertreatment of classic hemophilia, has ...
openaire +3 more sources